医学
荟萃分析
2型糖尿病
糖尿病
胰高血糖素样肽1受体
药理学
重症监护医学
内科学
内分泌学
受体
兴奋剂
作者
Brendon L. Neuen,Robert A. Fletcher,Lauren Heath,Adam Perkovic,Muthiah Vaduganathan,Sunil V. Badve,Katherine R. Tuttle,Richard E. Pratley,Hertzel C. Gerstein,Vlado Perkovic,Hiddo J.L. Heerspink
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2024-08-30
卷期号:150 (22): 1781-1790
被引量:94
标识
DOI:10.1161/circulationaha.124.071689
摘要
In people with type 2 diabetes, the cardiovascular and kidney benefits of GLP-1 receptor agonists are consistent regardless of SGLT2 inhibitor use.
科研通智能强力驱动
Strongly Powered by AbleSci AI